Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.63 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | LYN | P07948 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3901338 | 0.91 | SRC (0.70) | EGFRSRCTGFBR1PDGFRAPDGFRB | |
| SCHEMBL7485158 | 0.86 | FGFR2 (0.71) | PDGFRAPDGFRBKDRKITMET | |
| SCHEMBL22972011 | 0.85 | EGFR (0.60) | EGFRSRCTGFBR1PDGFRAPDGFRB | |
| SCHEMBL2747572 | 0.85 | PDGFRA (0.62) | PDGFRAPDGFRBKDRKITAURKA | |
| SCHEMBL22972241 | 0.83 | MET (0.65) | PDGFRAPDGFRBKDRKITAURKA | |
| SCHEMBL7482160 | 0.83 | PDGFRA (0.83) | PDGFRAKDR | |
| SCHEMBL7481076 | 0.83 | EGFR (0.78) | EGFRPDGFRAPDGFRB | |
| SCHEMBL7487378 | 0.83 | FGFR2 (0.77) | SRCTGFBR1PDGFRAPDGFRBKDR | |
| SCHEMBL31060325 | 0.83 | FGFR2 (0.78) | EGFRPDGFRAPDGFRBKDRKIT | |
| SCHEMBL17117826 | 0.83 | FGFR2 (0.78) | EGFRPDGFRAPDGFRBKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2022-12-08 | — | — | US | disclosed |
| WO-2021023888-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABL1, PHKB, EEF2K | EGFR 880/4885SRC 336/4885TGFBR1 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.